Intercept Pharmaceuticals, Inc. (ICPT)
- GlobeNewswire
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed. As a result of this transaction, Intercept’s international business has been divested and its international commercial and medical infrastru
- Simply Wall St.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
With the business potentially at an important milestone, we thought we'd take a closer look at Intercept...
- GlobeNewswire
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts highlighting the benefits of obeticholic acid (OCA) in individuals with primary biliary cholangitis (PBC) will be presented at the International Liver Congress™ 2022, the 57th Annual Meeting of the European Associat
